CASI Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on CASI Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date CASI Pharmaceuticals Inc Strategy Report
- Understand CASI Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for treating cancer and other unmet medical needs. The company’s product EVOMELA (melphalan for injection) an intravenous formulation for the treatment of multiple myeloma. It’s pipeline product portfolio includes CID-103 for treatment of multiple myeloma; CNTC 19 for hematological malignancies; ZEVALIN for treatment of relapsed/refractory, low-grade B-cell non-Hodgkin’s lymphoma (NHL); MARQIBO for treatment of Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL); BI-1206 for non-hodgkin's lymphoma and solid tumors; CB-5339 AML/MDS and solid tumors; Octreotide LAI for treatment of acromegaly and symptoms associated with neuroendocrine tumors. The company operates its subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.
CASI Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
EVOMELA – for multiple myeloma |
Pipeline |
BI-1206-non-Hodgkin’s lymphoma and solid tumors |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In August, the company entered into an agreement with Mundipharma International Corporation Limited for the commercialization of FOLOTYN. |
2023 | Official Trials/Tests | In January, the company announced the approval of Clinical Trial Application for CB-5339 by China National Medical Products Administration. |
2022 | Regulatory Approval | In December, the company announced the acceptance of New Drug Application for CNCT19 by China National Medical Products Administration. |
Competitor Comparison
Key Parameters | CASI Pharmaceuticals Inc | Hualan Biological Engineering Inc | Viva Biotech Holdings | Fennec Pharmaceuticals Inc | Cardiff Oncology Inc |
---|---|---|---|---|---|
Headquarters | China | China | China | United States of America | United States of America |
City | Beijing | Xinxiang | Shanghai | Research Triangle Park | San Diego |
State/Province | Beijing | Henan | Shanghai | North Carolina | California |
No. of Employees | 176 | 3,709 | 2,271 | 36 | 31 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Wei-Wu He, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2019 | 58 |
Alexander A. Zukiwski, M.D. | Chief Medical Officer | Senior Management | 2017 | 64 |
Fuqiang Zhang | Chief Commercial Officer | Senior Management | 2021 | 54 |
Chunhua Wang | Chief Operating Officer - CASI Pharmaceuticals (Beijing) Co | Senior Management | 2018 | - |
Larry Zhang | Principal Financial Officer; President | Senior Management | 2019 | 63 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward